Improvement in baroreflex function by an oral angiotensin receptor antagonist in rats with myocardial infarction.

Impaired baroreflex function is a factor responsible for poor prognosis in myocardial infarction patients. Using logistic function curves, we calculated the maximal gain of the baroreflex control of renal sympathetic nerve activity (RSNA) and heart rate in conscious Wistar-Kyoto and spontaneously hypertensive rats whose left anterior descending artery had been ligated 4 weeks earlier. We further investigated whether 3-week oral treatment with the angiotensin II type 1 receptor antagonist TCV-116 would improve the baroreflex in rats with myocardial infarction. The maximal gain of the mean arterial pressure-RSNA relation in spontaneously hypertensive rats with myocardial infarction and treated with vehicle (1.7 +/- 0.1% control per mm Hg) was smaller than the gain in sham-operated hypertensive rats (2.3 +/- 0.1% control per mm Hg). After 3-week oral treatment with TCV-116, the maximal gain of the arterial pressure-RSNA relation in hypertensive rats with myocardial infarction was 2.3 +/- 0.1% control per mm Hg and significantly greater than the gain in infarcted and vehicle-treated hypertensive rats. In hypertensive rats, the maximal gain of the arterial pressure-heart rate relation of infarcted and TCV-116-treated rats was larger than in infarcted and vehicle-treated rats but significantly smaller than in sham-operated rats. These results demonstrate that oral treatment with an angiotensin receptor antagonist is effective in restoring the impaired baroreflex caused by myocardial infarction and that endogenous angiotensin II is one of the critical factors involved in the impaired baroreflex in myocardial infarction.

[1]  J. Cutler,et al.  Blood Pressure and Mortality Among Men With Prior Myocardial Infarction , 1995 .

[2]  K. Kubo,et al.  Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl , 1993, The Journal of pharmacology and experimental therapeutics.

[3]  P. Schwartz,et al.  Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. A prospective study. , 1988, Circulation.

[4]  A J Camm,et al.  Baroreflex sensitivity and electrophysiological correlates in patients after acute myocardial infarction. , 1991, Circulation.

[5]  G. Dibona,et al.  ANG II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure. , 1995, The American journal of physiology.

[6]  S. S. Hull,et al.  Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. , 1991, Circulation research.

[7]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[8]  D. Averill,et al.  Renal nerve activity in rats with spontaneous hypertension: effect of converting enzyme inhibitor. , 1992, The American journal of physiology.

[9]  M. Creager.  Baroreceptor reflex function in congestive heart failure. , 1992, The American journal of cardiology.

[10]  O. Kjellgren,et al.  Heart rate variability and baroreflex sensitivity in myocardial infarction. , 1993, American heart journal.

[11]  S. Goldman,et al.  Baroreflex control of heart rate in rats with heart failure after myocardial infarction: effects of captopril. , 1992, Journal of Pharmacology and Experimental Therapeutics.

[12]  T. Saruta,et al.  Comparison of early and late start of antihypertensive agents and baroreceptor reflexes. , 1996, Hypertension.

[13]  T. Saruta,et al.  Baroreflex control of renal sympathetic nerve activity is potentiated at early phase of two-kidney, one-clip Goldblatt hypertension in conscious rabbits. , 1990, Circulation research.

[14]  T. Saruta,et al.  Differential modulation of baroreceptor sensitivity by long-term antihypertensive treatment. , 1995, Hypertension.

[15]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[16]  C. Kawai,et al.  Long‐Term prognosis after myocardial infarction: Univariate and multivariate analysis of clinical characteristics in 1,000 patients , 1993 .

[17]  M. Munger,et al.  Effect of Angiotensin-Converting Enzyme Inhibitors on Ventricular Remodeling and Survival following Myocardial Infarction , 1993, The Annals of pharmacotherapy.

[18]  F J Schoen,et al.  Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. , 1985, The American journal of pathology.

[19]  H. Drexler,et al.  Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. , 1994, Circulation.

[20]  M. Pfeffer,et al.  Myocardial Infarct Size and Ventricular Function in Rats , 1979, Circulation research.

[21]  H Just,et al.  Reflex versus tonic vagal activity as a prognostic parameter in patients with sustained ventricular tachycardia or ventricular fibrillation. , 1994, Circulation.

[22]  H. Selye,et al.  Simple Techniques for the Surgical Occlusion of Coronary Vessels in the Rat , 1960, Angiology.

[23]  G. Dibona,et al.  Reflex regulation of renal nerve activity in cardiac failure. , 1994, The American journal of physiology.

[24]  P. Schwartz,et al.  Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. , 1992, Circulation.